Pharmacopsychiatry 2020; 53(03): 141
DOI: 10.1055/s-0040-1710116
Abstracts
XIVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP

8 Serum concentrations of venlafaxine and risperidone and their metabolites from childhood to old age

S Fekete
1   Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg, Germany
,
M Scherf-Clavel
2   Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
,
M Gerlach
1   Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg, Germany
,
M Romanos
1   Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg, Germany
,
S Kittel-Schneider
2   Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
,
S Unterecker
2   Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
,
K Egberts
1   Department Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Center of Mental Health, University Hospital of Wuerzburg, Germany
› Author Affiliations
› Further Information
Also available at
 

Introduction Pharmacokinetic data about the antidepressant venlafaxine (VEN) and the antipsychotic risperidone (RIS) over the lifespan and especially in children and adolescents is lacking. To fill some of this gap, this study aims to investigate the relationship between age and serum concentrations of VEN and RIS and their metabolites.

Methods Drug serum levels of patients treated with VEN and RIS of the University Hospital of Würzburg, Germany, between 2015 and 2019 were retrospectively investigated.

Results For both substances, no age-dependent difference in metabolite to parent ratios (MPRs) was found. However, minors treated with VEN (N = 26) and RIS (N = 79) showed lower dose corrected concentrations of VEN and RIS than adults (n = 637 / 348) or elder adults (> 60 years) (n = 290 / 140). Moreover, 80 % of MPRs of RIS in minors were below the range of a “normal” CYP2D6 function in adults.

Conclusions We suggest minors’ higher renal clearance as an explanation for lower dose corrected concentrations of VEN and RIS. Metabolism of VEN or RIS by CYP2D6, characterized by MPRs, was not associated with age. However, MPRs of RIS are lower in minors, possibly due to a higher clearance of 9-OH-risperidone.



Publication History

Article published online:
30 April 2020

© Georg Thieme Verlag KG
Stuttgart · New York